Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

993 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma.
Yang C, You J, Pan Q, Tang Y, Cai L, Huang Y, Gu J, Wang Y, Yang X, Du Y, Ouyang D, Chen H, Zhong H, Li Y, Yang J, Han Y, Sun F, Chen Y, Wang Q, Weng D, Liu Z, Xiang T, Xia J. Yang C, et al. Among authors: xiang t. BMC Med. 2023 Aug 28;21(1):327. doi: 10.1186/s12916-023-03016-0. BMC Med. 2023. PMID: 37635247 Free PMC article.
Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma.
Yang J, Guo Z, Song M, Pan Q, Zhao J, Huang Y, Han Y, Ouyang D, Yang C, Chen H, Di M, Tang Y, Zhu Q, Wang Q, Li Y, He J, Weng D, Xiang T, Xia J. Yang J, et al. Among authors: xiang t. Front Immunol. 2023 Jul 21;14:1212577. doi: 10.3389/fimmu.2023.1212577. eCollection 2023. Front Immunol. 2023. PMID: 37545530 Free PMC article.
Correction: Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma.
Zhu Q, Zhong AL, Hu H, Zhao JJ, Weng DS, Tang Y, Pan QZ, Zhou ZQ, Song MJ, Yang JY, He JY, Liu Y, Li M, Hu WM, Yang CP, Xiang T, Chen MY, Ma G, Guo L, Xia JC. Zhu Q, et al. Among authors: xiang t. J Hematol Oncol. 2023 Nov 4;16(1):110. doi: 10.1186/s13045-023-01505-6. J Hematol Oncol. 2023. PMID: 37925485 Free PMC article. No abstract available.
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
Pan QZ, Zhao JJ, Liu L, Zhang DS, Wang LP, Hu WW, Weng DS, Xu X, Li YZ, Tang Y, Zhang WH, Li JY, Zheng X, Wang QJ, Li YQ, Xiang T, Zhou L, Yang SN, Wu C, Huang RX, He J, Du WJ, Chen LJ, Wu YN, Xu B, Shen Q, Zhang Y, Jiang JT, Ren XB, Xia JC. Pan QZ, et al. Among authors: xiang t. Signal Transduct Target Ther. 2024 Apr 3;9(1):79. doi: 10.1038/s41392-024-01788-2. Signal Transduct Target Ther. 2024. PMID: 38565886 Free PMC article. Clinical Trial.
993 results